Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

DOI Web Site Web Site PubMed 参考文献13件 オープンアクセス
  • Uchida Mayako
    Department of Pharmacy, Kyushu University Hospital Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences
  • Nakamura Tsutomu
    Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences
  • Shima Takahiro
    Department of Medicine and Biosystemic Science and, Kyushu University Graduate School of Medical Sciences
  • Yoshimoto Goichi
    Department of Medicine and Biosystemic Science and, Kyushu University Graduate School of Medical Sciences
  • Kato Koji
    Department of Medicine and Biosystemic Science and, Kyushu University Graduate School of Medical Sciences
  • Hosohata Keiko
    Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences
  • Miyamoto Toshihiro
    Department of Medicine and Biosystemic Science and, Kyushu University Graduate School of Medical Sciences
  • Akashi Koichi
    Department of Medicine and Biosystemic Science and, Kyushu University Graduate School of Medical Sciences

この論文をさがす

説明

<p>Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.</p>

収録刊行物

参考文献 (13)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ